TG Therapeutics (TGTX) Misses Q4 EPS by 12c

TG Therapeutics (NASDAQ: TGTX) reported Q4 EPS of ($0.39), $0.12 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $80 thousand versus the consensus estimate of $1.83 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Pfizer reaffirms 2026 guidance after CFO transition news
• FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group